


Assay development, validation & testing for an mRNA-1273 COVID-19 Vaccine Clinical Trial

INTRODUCTION / OVERVIEW

Vaccine development has historically been a long, complex process, requiring evaluation for immunogenicity, safety and protective efficacy. With this complexity, many factors can affect the probability of licensure and ultimate public health impact. However, with the recent emergence of a novel coronavirus, and the subsequent pandemic, research began on the first vaccine development efforts leveraging an mRNA vaccine platform. This new platform offered the advantages of both efficiency and flexibility in immunogen design, which proved critical for developing a therapeutic that could provide protective immunity in the face of the SARS COVID-19 outbreak, for which much of the world was unprepared.

SITUATION / CHALLENGE

As a leading provider of assay development and testing services for clinical development of vaccines and antivirals, Eurofins Viracor has supported multiple clinical trials for vaccine manufacturers. So, when Moderna was gearing up for clinical studies of their mRNA-1273 COVID-19 vaccine candidate, developed in collaboration with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID), they reached out to Viracor to provide quantitative polymerase chain reaction (qPCR) assay development, validation, and testing. Eurofins Viracor was already gearing up to enter the fight against the COVID-19 pandemic with the launch of their new Coronavirus (COVID-19) SARS-CoV-2 RT-PCR test. A qPCR assay that the US Food and Drug Administration (FDA) would later show to have the highest sensitivity of any they evaluated.



SOLUTION

In support of the Moderna mRNA-1273 vaccine clinical trial (COVE Study), Eurofins Viracor quickly validated the assay, and carried out pivotal RT-qPCR testing for both the Phase II and Phase III portions of the clinical trial to assess the safety and efficacy of the Moderna vaccine candidate against novel coronavirus infection.

After validating a sensitive and robust qPCR assay for Moderna's clinical study, that was bridged to their EUA assay, the Eurofins Viracor laboratory team performed over 2,000 Phase II tests, and more than 85,000 tests (on NP swab and saliva samples) to support their >30,000 subject Phase III trial.

The SARS-CoV-2 specific RT-qPCR assay was used to detect SARS-CoV-2 RNA in upper respiratory (nasal/nasopharyngeal wash and swab) and bronchoalveolar lavage (BAL) samples. This assay, provided qualitative detection of SARS-CoV-2 virus RNA in specimens collected from individuals in the trial. The SARS-CoV-2 RT-qPCR assay was also used for quantitative detection of viral RNA in both nasopharyngeal swabs and saliva samples to assess viral load.

Eurofins Viracor also performed a spike-gene sequencing assay (SARS-CoV-2 S gene NGS assay) and a Whole Genome Sequencing Assay (WGS) on nasal swabs to assess SARS-CoV2 variants in the study population.

In addition to the SARS-CoV-2 testing, Eurofins Viracor provided qualitative detection and differentiation of respiratory pathogens for 20 different viral and bacterial respiratory organisms associated with respiratory tract infection.

Lastly, as a function of the ongoing pandemic, Eurofins and Moderna overcame some of the most extreme logistical and inventory challenges a clinical trial can experience, to deliver consistent high-quality results in a timely manner.

OUTCOME

Viracor's contribution was essential to the successful completion of the COVE study trial, and ultimately the Emergency Use Authorization (EUA) by the U.S. FDA of the mRNA-1273 vaccine candidate for the prevention of COVID-19 on December 18, 2020; with subsequent approvals by regulatory agencies around the globe.

The RT-qPCR assay designed by Eurofins Viracor, has also now been utilized world-wide to provide >20 million COVID-19 infection results.

In an era where therapy and vaccine efficacy are threatened by variants, Eurofins Viracor BioPharma continues to battle the global health threat by providing immunity testing and whole genome sequencing of SARS-COV-2.



Viracor
BioPharma



35 years of
Scientific
Experience

Trusted
Laboratory
Partner



CAP Accredited
CLIA Licensure

Over 3,000
validated assays



Contact us today to discover
how the Eurofins Viracor
team can make the
difference in your projects.

Eurofins Viracor Biopharma
1001 NW Technology Dr.
Lee's Summit, MO 64086
USA
Tel +1 800 305 5198
Fax +1 816 347 0143

clinicaltrials@eurofins-viracor.com
eurofins-viracor.com/biopharma

All trademarks mentioned herein are the property
of Eurofins or their respective owners.

Lit No. EBPS-VE-US-ADCS-11/2021
Printed in the USA.

© 2021 Eurofins Viracor BioPharma is an
independent member of Eurofins
BioPharma Services